Paul Schuler
Shreveport, LANPI 1881662682
Payments from drug & device makers
$2,880in general payments, 2019–2025
Across 197 payments — averaging $14.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$632
- Actelion Pharmaceuticals US, Inc.$514
- AstraZeneca$343
- Boehringer Ingelheim$249
- United Therapeutics Corporation$235
- Genentech USA, Inc.$173
- plus $735 from 15 others
What the payments were for
- Food & beverage$2,876100%
- Education$40%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
19
20
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 51 | $632 |
| Actelion Pharmaceuticals US, Inc. | 54 | $514 |
| AstraZeneca | 20 | $343 |
| Boehringer Ingelheim | 15 | $249 |
| United Therapeutics Corporation | 13 | $235 |
| Genentech USA, Inc. | 11 | $173 |
| Philips North America LLC | 6 | $164 |
| Insmed, Inc. | 3 | $151 |
| Mylan Specialty L.p. | 5 | $86 |
| Merck | 4 | $48 |
| Grifols USA, LLC | 2 | $43 |
| Novartis | 2 | $42 |
| La Jolla Pharmaceutical Company | 2 | $34 |
| Sanofi-aventis U.S. LLC | 2 | $33 |
| Regeneron Healthcare Solutions, Inc. | 1 | $29 |
| Paratek Pharmaceuticals, Inc. | 1 | $23 |
| Gilead | 1 | $21 |
| Bayer | 1 | $19 |
| Johnson & Johnson | 1 | $16 |
| Circassia Inc. | 1 | $15 |
| Sandoz | 1 | $13 |
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.